Author Archives: Patricia Inacio, PhD

Lab Study Shows Positive Effects of Adcirca in Treatment of PAH

Adcirca (tadalafil) exerts a variety of positive effects that may explain why the therapy improves idiopathic pulmonary arterial hypertension (IPAH), according to an in vitro study. The study, “Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro,” was published…

Bellerophon Updates Pulsed, Inhaled Nitric Oxide Clinical Trials for PH, Related Disorders

Bellerophon Therapeutics has updated clinical trials testing its investigative INOpulse system for several forms of pulmonary hypertension (PH). The update is part of the company’s second-quarter 2017 financial report. The INOvation-1 trial (NCT02725372) seeks to evaluate the safety, tolerability and effectiveness of pulsed, inhaled nitric oxide (iNO) compared to placebo…

Phase 4 Registry Evaluating Inomax Gas in Premature Babies with PH Enrolls First Participant

The Phase 4 multicenter, observational PaTTerN registry evaluating the use of Inomax (nitric oxide) in newborns with pulmonary hypertension (PH) has enrolled its first patient, Mallinckrodt Pharmaceuticals announced. The registry (NCT03132428) is actively recruiting participants, said the British drug conglomerate. Persistent PH in newborns is a serious, sometimes fatal, condition marked by increased pulmonary vascular pressure.

Long-term Prostacyclin Use Increases Risk of a Heart Problem After a Lung Transplant, Study Reports

Pulmonary hypertension patients who receive prostacyclin for a long time are at higher risk of developing cardiovascular complications after a lung transplant, a Japanese study reports. The research, published in the International Heart Journal, was titled “High Frequency of Acute Adverse Cardiovascular Events After Lung Transplantation in Patients…

Short Survival of Only 4 Years Still Characterizes Systemic Sclerosis Patients with PAH, Australian Study Finds

The average systemic sclerosis (SSc) patient burdened with pulmonary arterial hypertension (PAH) lives only four years after diagnosis, finds an Australian study,  “Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension,” that appeared in the journal Arthritis Research & Therapy. PAH is a serious…

Study Proves OCT Imaging Technique Useful for Managing PAH in Systemic Sclerosis Patients

An imaging technique called optical coherence tomography (OCT) can effectively determine abnormalities in the lung vasculature of pulmonary arterial hypertension (PAH) patients with systemic sclerosis (SSc), a study shows. The study, “Optical coherence tomography evaluation of pulmonary arterial vasculopathy in Systemic Sclerosis,” appeared in the journal Scientific…

Analysis Ranks Letairis Best Endothelin Receptor Antagonist for PAH Treatment

Letairis (ambrisentan) was the most efficient, robust therapeutic among endothelin receptor antagonists (ERAs) to treat pulmonary arterial hypertension (PAH), according to a study that compared the drug to three other therapies: Thelin (sitaxsentan), Tracleer (bosentan) and Opsumit (macitentan). The study, “Comparative efficacy and acceptability of endothelin receptor antagonists for…

Multiple Sclerosis Treatment, Tecfidera, Seen to Ease Fibrosis and Inflammation in Early PAH Study

The approved multiple-sclerosis treatment Tecfidera was seen to improve pulmonary arterial hypertension (PAH) and inhibit lung fibrosis in mice by targeting multiple signaling pathways in a recent study. The research, “Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways,” was published in the journal…